Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.…
Ginkgo Bioworks Holdings Inc (DNA) Q3 2026 Earnings Call Highlights: Cost Cuts, First Big ...
Ginkgo Bioworks Holdings (NYSE: DNA) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 485 employees.
The shares were at 7.460 USD on 20 November 2026, down 4.1% over 52 weeks. Its 52-week range is 5.370 USD to 18.22 USD: the price is 59.1% below the high and 38.9% above the low.
Its market capitalisation is 483.54M USD.
Ginkgo Bioworks Holdings reports return on equity of -61.5%, an operating margin of -202.5% and revenue down 5.7% year over year.
Its debt exceeds its cash by 111.84M USD, a debt-to-equity ratio of 0.86. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Underperform; their mean price target of 8.000 USD is 7.2% above the current price. The next earnings report is expected on 25 February 2027.